Wednesday, June 3, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Jun 3, 2026
Merck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens
background ▾
- •Merck is considering emergency or expedited regulatory pathways to deploy molnupiravir against Ebola, leveraging an existing safety/manufacturing database from COVID-19 EUA
- •Success would depend on generating sufficient efficacy evidence and securing rapid regulatory approvals from African health authorities and WHO, which typically require clinical data
- •Watch for announcements on clinical studies, EUA applications, and partnership agreements with health organizations; supply chain readiness will be critical given manufacturing constraints
Merck & Co.molnupiravirLagevrio
→ Read original articlePolicy•Fierce Pharma•Jun 3, 2026
ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection
background ▾
- •Cingulate's lead ADHD drug rejected by FDA on manufacturing/CMC grounds—not efficacy or safety—indicating facility or process deficiencies rather than clinical issues.
- •This is Cingulate's first major regulatory setback and delays its first market approval, likely impacting cash runway and investor confidence.
- •Watch for Cingulate's resubmission timeline, any manufacturing partner changes, and whether the company discloses specific CMC deficiencies or facility issues.
Cingulate Therapeutics
→ Read original articlePolicy•Fierce Biotech•Jun 2, 2026
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
background ▾
- •FDA has adopted a class-wide safety position: any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of specific subunit targeted, closing the regulatory path for pociredir despite mechanistic differentiation arguments
- •Ipsen's Tazverik withdrawal (secondary hematologic malignancies in phase 1b/3) has triggered FDA enforcement across the PRC2 inhibitor landscape, affecting even earlier-stage competitors with different target selectivity
- •Fulcrum faces existential business risk with cash reserves of $333M becoming a liability rather than asset; watch for M&A activity, asset sales, or pivot announcements in HbF inducers; monitor whether other PRC2 programs (e.g., GSKE's euchromatin histone methyltransferase inhibitors) face similar FDA scrutiny
Fulcrum TherapeuticsIpsenEpizymepociredirTazverikalisertib
→ Read original articlePolicy•Fierce Pharma•Jun 3, 2026
Marilyn Monroe and Amy Schumer profiled in endometriosis awareness push
background ▾
- •New nonprofit launched to address endometriosis research, treatment, and awareness gaps through documentary storytelling
Policy•Fierce Pharma•Jun 3, 2026
Merck shrinks headcount by 88 in New Jersey as $3B cost-cutting scheme advances
background ▾
- •Merck is executing Phase 2 of a $3B cost-reduction program through workforce reductions, with 88 jobs cut at New Jersey operations
- •The layoffs are part of a multiyear optimization strategy announced in July, suggesting further headcount impacts may follow
Merck
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jun 2, 2026
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
background ▾
- •Civorebrutinib demonstrated clinical and immunologic remission in phase 1/2 PMN trial with stable kidney function at 52 weeks, providing a mechanistic rationale for expansion into additional immune-mediated kidney diseases.
- •Travere's acquisition positions the company to address multiple orphan kidney indications with a single mechanism, building on recent Filspari commercialization and creating potential for a multi-indication franchise.
- •Monitor phase 2/3 initiation timelines in FSGS, IgAN, and other indications; regulatory pathway and potential for expedited designations will be critical to value realization of milestone payments.
Travere TherapeuticsEverest MedicinesSinoventcivorebrutinibFilspari
→ Read original articleMarket Access•Fierce Biotech•Jun 2, 2026
MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
background ▾
- •MindMaze is executing a deliberate portfolio rationalization to refocus exclusively on neurology digital therapeutics, abandoning non-core rare disease programs acquired through merger integration.
- •The company is targeting ~33% cost reduction through operational streamlining, signaling financial pressure and potential cash runway concerns in the current market environment.
- •Monitor for completion timelines on non-neurology asset sales and whether the cost cuts enable sustainable operations or if further financing/partnership becomes necessary.
MindMaze TherapeuticsRelief TherapeuticsNeuroXRLF-OD032sapropterin dihydrochlorideIzar
→ Read original articleMarket Access•STAT News•Jun 3, 2026
Opinion: The medical-billing AI arms race between providers and insurance
background ▾
- •Hospital and insurer AI systems are engaged in largely opaque automated billing disputes where patients bear financial consequences without meaningful human review or intervention
- •AI-driven 'ambient listening' and coding optimization tools create financial incentives to code secondary diagnoses (complications and comorbidities) more aggressively than clinical reality warrants, fundamentally separate from underlying healthcare cost drivers like consolidation
Market Access•Fierce Pharma•Jun 3, 2026
Rising Stars: WPP’s Meghan O’Hora on the ‘complex puzzle’ of oncology drug marketing
background ▾
- •This is an opinion/interview piece with minimal substantive news content relevant to pharma professionals making business decisions
WPP
→ Read original articleMarket Access•Fierce Pharma•Jun 3, 2026
Eli Lilly's ultimatum to hospitals: Send 340B claims data by June 8 or lose discounts
background ▾
- •Eli Lilly's mandatory claims data submission deadline creates immediate compliance pressure on hospitals and risks disrupting 340B program participation if enforced
- •Hospital industry groups are mounting legal and political opposition, signaling potential litigation and regulatory intervention that could determine the validity of manufacturer-imposed 340B compliance requirements
- •The outcome will establish precedent for whether manufacturers can unilaterally impose data transparency requirements as a condition of 340B participation, affecting industry-wide practices
Eli Lilly
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 2, 2026
ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push
background ▾
- •Onvansertib demonstrated clinically meaningful PFS improvement over control in the FOLFIRI/bevacizumab arm (hazard ratio 0.55–0.57), but the regimen-specific efficacy difference raises concerns about biologic mechanism and generalizability
- •The drug's restriction to ~30% of frontline colorectal cancer patients due to FOLFOX/bev failure significantly narrows the commercial opportunity and may impede physician adoption despite positive phase 2 data
- •Cardiff's severe cash constraint ($46.1M; cash runway to Q1 2027) combined with phase 3 funding needs creates substantial dilution risk; watch for partnership announcements or financing activity over next 6–12 months
Cardiff Oncologyonvansertib
→ Read original articleClinical Trials•Fierce Pharma•Jun 3, 2026
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
background ▾
- •Giredestrant failed its primary endpoint in phase 3 first-line breast cancer, a major disappointment for a drug positioned as a potential blockbuster
- •Roche is pursuing an adjuvant (post-surgical) indication for giredestrant following the first-line flop, suggesting belief in the mechanism despite clinical setback
- •Investor and payer confidence in giredestrant's commercial viability will depend on adjuvant trial success and competitive positioning versus existing SERDs and endocrine therapies
Rochegiredestrant
→ Read original articleClinical Trials•Fierce Pharma•Jun 3, 2026
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
background ▾
- •Phase 3 primary endpoint met with normalization of key disease progression marker at 52 weeks in PBC patients
- •Positive data support potential label expansion and broader patient population eligibility
- •Next critical milestone is regulatory submission and approval decision from FDA/EMA
Gilead SciencesLivdelzi
→ Read original articleClinical Trials•Fierce Biotech•Jun 2, 2026
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
background ▾
- •NewLimit's platform uses mRNA-delivered transcription factors to reprogram aged cells, with preclinical data showing enhanced regenerative capacity and metabolic resilience in old liver tissue and animal models
- •The company achieved clinical-stage readiness faster than anticipated (months vs. 3-4 years), suggesting either exceptional scientific progress or inherent platform versatility, though results are not yet independently validated
- •Liver disease represents an initial market with substantial commercial opportunity (metabolic syndrome affects ~50% of adults over 60), but clinical efficacy in humans remains undemonstrated and regulatory pathway for mRNA cellular reprogramming therapies is unproven
NewLimitFounders FundKleiner Perkins
→ Read original articleClinical Trials•Endpoints News•Jun 2, 2026
What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
background ▾
- •VEGF-targeted cancer drugs are underperforming relative to earlier expectations that they would become blockbuster therapies comparable to checkpoint inhibitors
- •ASCO26 data provided limited clarity on the path forward for VEGF inhibitors, suggesting a more constrained commercial outlook than previously projected
Keytruda
→ Read original article